{"DataElement":{"publicId":"5527455","version":"1","preferredName":"Hypogammaglobulinemia PostBMT Response Category","preferredDefinition":"Identification of the status of hypogammaglobulinemia post bone marrow transplantation.","longName":"HYPOGAM_PBMT_RES_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"5527450","version":"1","preferredName":"Hypogammaglobulinemia Timepoint Post Transplantation Disease Response","preferredDefinition":"A specific point in the time continuum, including those established relative to an event._Happening at a time subsequent to a reference time; later in time or order._Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.","longName":"3297531v1.0:5525883v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"3297531","version":"1","preferredName":"Hypogammaglobulinemia","preferredDefinition":"A condition in which the level of immunoglobulins (antibodies) in the blood is low and the risk of infection is high.","longName":"C26931","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypogammaglobulinemia","conceptCode":"C26931","definition":"A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B024AF61-9308-89E5-E040-BB89AD433E35","latestVersionIndicator":"Yes","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"ONEDATA","dateModified":"2011-10-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5525883","version":"1","preferredName":"Timepoint Post Transplantation Disease Response","preferredDefinition":"A specific point in the time continuum, including those established relative to an event.:Happening at a time subsequent to a reference time; later in time or order.:Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C68568:C38008:C15342:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Timepoint","conceptCode":"C68568","definition":"A specific point in the time continuum, including those established relative to an event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F27A5BA-2AFC-6999-E053-F662850A8C54","latestVersionIndicator":"Yes","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"ONEDATA","dateModified":"2016-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F37C10C-BED8-2168-E053-F662850AC503","latestVersionIndicator":"Yes","beginDate":"2016-10-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-19","modifiedBy":"REEVESD","dateModified":"2016-10-21","changeDescription":"Curated to support NCI CCR Primary Immunosuppression CRF template.10.21.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5527451","version":"1","preferredName":"Hypogammaglobulinemia PostBMT Response Category","preferredDefinition":"Category; used informally to mean a class of things.","longName":"HYPOGAM_BMT_RESP_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"80","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Persistent hypogammaglobulinemia akin to pre-BMT values","valueDescription":"Persistent Hypogammaglobulinemia Like Prior Transplantation Values","ValueMeaning":{"publicId":"5527452","version":"1","preferredName":"Persistent Hypogammaglobulinemia Like Prior Transplantation Values","longName":"5527452","preferredDefinition":"Retained; never-ceasing.: Earlier in time or order.: Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.: A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Persistent","conceptCode":"C43623","definition":"Retained; never-ceasing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hypogammaglobulinemia","conceptCode":"C26931","definition":"A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F37C10C-BF03-2168-E053-F662850AC503","latestVersionIndicator":"Yes","beginDate":"2016-10-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3F37C10C-BF1C-2168-E053-F662850AC503","beginDate":"2016-10-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-19","modifiedBy":"ONEDATA","dateModified":"2016-10-19","deletedIndicator":"No"},{"value":"Resolved after transient need for immunoglobulin replacement therapy","valueDescription":"Resolved with Temporary Immunoglobulin Replacement Therapy ","ValueMeaning":{"publicId":"5527453","version":"1","preferredName":"Resolved with Temporary Immunoglobulin Replacement Therapy ","longName":"5527453","preferredDefinition":"Not permanent; not lasting; lacking continuity or regularity.: Any of the structurally related glycoproteins that function as antibodies. They are divided into five classes (IGA, IGD, IGE, IGG, IGM) on the basis of structure and biological activity.: Administration of a body substance to compensate for the loss, as from disease or surgery, of a gland or tissue that would normally produce the substance.: Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temporary","conceptCode":"C53288","definition":"Not permanent; not lasting; lacking continuity or regularity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Immunoglobulin","conceptCode":"C572","definition":"Any of the structurally related glycoproteins that function as antibodies. They are divided into five classes (IGA, IGD, IGE, IGG, IGM) on the basis of structure and biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Replacement Therapy","conceptCode":"C15471","definition":"Administration of a body substance to compensate for the loss, as from disease or surgery, of a gland or tissue that would normally produce the substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Physiologic Resolution","conceptCode":"C25655","definition":"Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F37C10C-BF2B-2168-E053-F662850AC503","latestVersionIndicator":"Yes","beginDate":"2016-10-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3F37C10C-BF44-2168-E053-F662850AC503","beginDate":"2016-10-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-19","modifiedBy":"ONEDATA","dateModified":"2016-10-19","deletedIndicator":"No"},{"value":"Resolved without further immunoglobulin therapy","valueDescription":"Resolved Without Immunoglobulin Therapy","ValueMeaning":{"publicId":"5527454","version":"1","preferredName":"Resolved Without Immunoglobulin Therapy","longName":"5527454","preferredDefinition":"Used to indicate the absence or lack of something or someone.: Any of the structurally related glycoproteins that function as antibodies. They are divided into five classes (IGA, IGD, IGE, IGG, IGM) on the basis of structure and biological activity.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Immunoglobulin","conceptCode":"C572","definition":"Any of the structurally related glycoproteins that function as antibodies. They are divided into five classes (IGA, IGD, IGE, IGG, IGM) on the basis of structure and biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Physiologic Resolution","conceptCode":"C25655","definition":"Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F37C10C-BF53-2168-E053-F662850AC503","latestVersionIndicator":"Yes","beginDate":"2016-10-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3F37C10C-BF6C-2168-E053-F662850AC503","beginDate":"2016-10-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-19","modifiedBy":"ONEDATA","dateModified":"2016-10-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2433877","version":"1","preferredName":"Category","preferredDefinition":"Category; used informally to mean a class of things.","longName":"C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"062E16DD-4D2F-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"3F37C10C-BEEB-2168-E053-F662850AC503","latestVersionIndicator":"Yes","beginDate":"2016-10-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-19","modifiedBy":"REEVESD","dateModified":"2016-10-21","changeDescription":"Curated to support NCI CCR Primary Immunodeficiency CRF Template.  Value sets are prescribed for that specific set of requirements.10.21.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Resolution after BMT","type":"Preferred Question Text","description":"Resolution after BMT","url":null,"context":"CCR"}],"origin":"C3D:Central Cancer Clinical Database","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"3F382605-A59F-622D-E053-F662850A1293","latestVersionIndicator":"Yes","beginDate":"2016-10-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-19","modifiedBy":"REEVESD","dateModified":"2016-10-21","changeDescription":"Curated to support NCI CCR Primary Immunosuppression CFR Template.10.21.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}